Safety and Immunogenicity of inactivated COVID-19 vaccine in Thai adults

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210308003

Enrollment

185

Registered

2021-03-08

Start date

2021-03-05

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Safety and Immunogenicity of inactivated COVID-19 vaccine in Thai adults COVID-19, Vaccine, inactivated, adults

Interventions

No intervention

No Intervention No treatment

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Healthy Thai adults aged between 18-60 years 2. Willing to be immunized with COVID-19 vaccine 3. Intend to be available for follow-up visits and phone call through 12 months postvaccination

Exclusion criteria

Exclusion criteria: 1. Subjects with history of COVID-19, asymptomatic SARS-CoV-2 infection or pre-existing antibodies to SARS-CoV-2 2. Previous severe reaction or allergy to any components in the COVID-19 vaccine 3. History of hospitalization within the past one month before injection. 4. Serious underlying medical condition (e.g., immunosuppressive disease or receiving immunosuppressive therapy, human immunodeficiency virus (HIV) infection) 5. Pregnant women, lactating women or women who are planning to become pregnant

Design outcomes

Primary

Measure	Time frame
Immunogenicity 3 months Antibodies against SARS-COV-2	—

Secondary

Measure	Time frame
Safety 7 days Records of adverse events	—

Countries

Thailand

Contacts

Public Contactsaovanee Benjamanukul

Banphaeo General Hospital

saovanee.ben@gmail.com663419555

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026